Proseek Bio raises $1.5 million to bring ovarian cancer blood test to market
Up to 80% of surgeries for women with suspected ovarian cancer turn out to be unnecessary. Proseek Bio wants to change that.
If you have an ovarian cyst, there is currently only one way to confirm with certainty whether it is cancerous: open surgery. In up to 80% of cases, that surgery proves unnecessary.
For the one in five women who develop an ovarian cyst, Proseek Bio aims to reduce these unnecessary surgeries with its OC-Triage blood test.
“The challenge is that the type of biomarkers that researchers have been looking for have not been accurate enough. With our technology, we believe that we can achieve the accuracy that’s needed for clinical adoption,” Proseek Bio founder Dr. Michelle Hill told Capital Brief.
The Brisbane-based startup has raised $1.5 million in an oversubscribed seed round to commercialise its blood test technology and speed up the diagnosis of one of the deadliest cancers affecting women.
